Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $7.71, for a total transaction of $169,620.00. Following the completion of the transaction, the director owned 1,144,391 shares in the company, valued at approximately $8,823,254.61. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vir Biotechnology Trading Down 1.5%

VIR stock traded down $0.11 during mid-day trading on Tuesday, hitting $7.60. 570,810 shares of the company were exchanged, compared to its average volume of 1,895,323. The stock has a market capitalization of $1.06 billion, a PE ratio of -2.11 and a beta of 1.39. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $10.67. The business has a 50 day simple moving average of $6.43 and a 200-day simple moving average of $5.72.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.47). Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.98 million. During the same quarter last year, the firm earned ($1.56) earnings per share. The business’s revenue for the quarter was up .8% compared to the same quarter last year. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on VIR. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VIR. AQR Capital Management LLC lifted its stake in Vir Biotechnology by 2,088.4% in the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after buying an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Vir Biotechnology in the 1st quarter worth about $359,000. Goldman Sachs Group Inc. raised its stake in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares during the last quarter. Woodline Partners LP raised its position in Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after buying an additional 331,701 shares during the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.